CEL-SCI Corporation reported that its Multikine® (Leukocyte Interleukin, Injection) cGMP dedicated manufacturing facility commissioning has been completed. Originally constructed to supply Multikine for the world?s largest global pivotal Phase 3 trial in locally advanced squamous cell carcinoma of the head and neck, CEL-SCI?s facility has been expanded and upgraded in preparation for the Company?s submission of Multikine for regulatory approval and commercial scale manufacturing. In keeping with CEL-SCI Validation Master Plan, industry standards, International Society for Pharmaceutical Engineering (ISPE) guidelines, International Conference for Harmonization (ICH), and in compliance with regulatory guidelines, CEL-SCI undertook commissioning and qualifying the facility?s utilities, systems, and equipment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 USD | +2.34% |
|
+6.50% | -51.84% |
Jul. 08 | Cel-Sci Appoints Robert Watson Board's Chair | MT |
Jul. 08 | CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.84% | 70.95M | |
+7.40% | 101B | |
+7.76% | 42.18B | |
-14.37% | 32.26B | |
+80.29% | 29.79B | |
-12.27% | 16.06B | |
+2.33% | 14.45B | |
-8.56% | 12.01B | |
+182.74% | 10.71B | |
+4.38% | 8.89B |
- Stock Market
- Equities
- CVM Stock
- News CEL-SCI Corporation
- CEL-SCI Corporation Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug